Future studies should focus on a direct comparison of IL-4 and IL-13 as well as their cytokine-specific receptor subunits (i.e., IL-2Rγ and IL-13Rα1, respectively) in the context of cardiovascular disease in vivo to validate the therapeutic potential of targeting one cytokine over the other. The gene discussed is IL4; the disease is cardiovascular disorder.